Contributions of the international plant science community to the fight against human infectious diseases – part 1: epidemic and pandemic diseases

Maria Lobato Gómez, Xin Huang, Derry Alvarez, Wenshu He, Can Baysal, Changfu Zhu, Victoria Armario-Najera, Amaya Blanco Perera, Pedro Cerda Bennasser, Andera Saba-Mayoral, Guillermo Sobrino-Mengual, Ashwin Vargheese, Rita Abranches, Isabel Alexandra Abreu, Shanmugaraj Balamurugan, Ralph Bock, Johannes Buyel, Nicolau da Cunha, Henry Daniell, R. FallerAndré Folgado, Iyappan Gowtham, Suvit Häkkinen, Kumar Shashi, Satish Kumar, C. Lacorte, G.P. Lomonossoff, Ines Luís, Julian K.C. Ma, K. McDonald, Andre Murad, Somen Nandi, Barry O'Keef, Kirsi-Marja Oksman-Candentey, Subramanian Parthiban, Mathew J. Paul, Daniel Ponndorf, Elibio Rech, Julio C.M. Rodrigues, Stephanie Ruf, S. Schilberg, Jennifer Schewstka, Priya S. Shah, Rahul singh, Eva Stöger, R.M. Twyman, Inchakalody Varghese, Vianna, Gina Webster, R.H.P. Wilbers, T. Capell*, P. Christou*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

17 Citations (Scopus)

Abstract

Infectious diseases, also known as transmissible or communicable diseases, are caused by pathogens or parasites that spread in communities by direct contact with infected individuals or contaminated materials, through droplets and aerosols, or via vectors such as insects. Such diseases cause ~17% of all human deaths and their management and control places an immense burden on healthcare systems worldwide. Traditional approaches for the prevention and control of infectious diseases include vaccination programs, hygiene measures, and drugs that suppress the pathogen, treat the disease symptoms, or attenuate aggressive reactions of the host immune system. The provision of vaccines and biologic drugs such as antibodies is hampered by the high cost and limited scalability of traditional manufacturing platforms based on microbial and animal cells, particularly in developing countries where infectious diseases are prevalent and poorly controlled. Molecular farming, which uses plants for protein expression, is a promising strategy to address the drawbacks of current manufacturing platforms. In this review article, we consider the potential of molecular farming to address healthcare demands for the most prevalent and important epidemic and pandemic diseases, focusing on recent outbreaks of high-mortality coronavirus infections and diseases that disproportionately affect the developing world
Original languageEnglish
Pages (from-to)1901-1920
JournalPlant Biotechnology Journal
Volume19
Issue number10
Early online date28 Jun 2021
DOIs
Publication statusPublished - 2021

Keywords

  • COVID-19
  • HIV/AIDS
  • Molecular farming
  • plant-made pharmaceuticals
  • SARS-CoV-2

Fingerprint

Dive into the research topics of 'Contributions of the international plant science community to the fight against human infectious diseases – part 1: epidemic and pandemic diseases'. Together they form a unique fingerprint.

Cite this